Crohn's FistulaPhase 1NCT00992485
Safety and Efficacy Study of Autologous Cultured Adipose -Derived Stem Cells for the Crohn's Fistula
A Phase 1 study testing ADIPOPLUS in people with Crohn's Fistula, run by Anterogen Co., Ltd. at 1 site in South Korea.
Trial summary
Up to date, a sure cure for Crohn's fistula has not known and the fistula recurrence rate is high. On 15 October 2008, orphan drug designation was granted by Korea FDA to Anterogen Co. Ltd., for human adipose-derived stem cell. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Crohn's Fistula
- What is being tested?
- ADIPOPLUS
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 9 participants
- Where
- 1 siteSouth Korea
- Study dates
- Nov 2008to Mar 2010
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Older than 18 years
- Prior diagnosis of Crohn's disease
- patients who have Crohn's fistula
- negative for urine beta-HCG for woman of childbearing age
- agreement to participate, with signed informed-consent
Who cannot join
- patients who have allergy to bovine-derived materials or an anesthetic
- patients with a diagnosis of auto immune disease except for Crohn's disease
- Diagnosis of HBV, HCV, HIV and other infectious disease
- Patients who have a symptom of septicemia
- Patients with a diagnosis of active Tuberculosis
- Patients who are pregnant or breast-feeding
Show all 13Show fewer
- Patients who are unwilling to use an "effective" method of contraception during the study
- Patients with a diagnosis of Inflammatory Bowel Disease except for Crohn's disease
- Patients who is sensitive to Fibrin glue
- Patients who have a clinically relevant history of abuse of alcohol or drugs
- Insufficient adipose tissue for manufacturing of ADIPOPLUS
- Patients who are considered not suitable for the study by investigator
- Patients who have history of surgery for malignant cancer in the past 5 years
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Phase I Dose Escalation Clinical Study of ADIPOPLUS (Autologous Cultured Adipose-derived Stem Cell) for the Treatment of Crohn's Fistula to Evaluate Safety and Efficacy
Up to date, a sure cure for Crohn's fistula has not known and the fistula recurrence rate is high. On 15 October 2008, orphan drug designation was granted by Korea FDA to Anterogen Co. Ltd., for human adipose-derived stem cell. In this study, patients are given injection of ADIPOPLUS in fistula site and followed for 8 weeks to test the safety and efficacy.
- Conditions
- Crohn's Fistula
- Being tested
- ADIPOPLUS
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ADIPOPLUSDrug
autologous adipose-derived stem cell
| Study group | Role | What they receive |
|---|---|---|
| autologous adipose derived stem cell | Experimental | Not described Receives: Drug: ADIPOPLUS |
What is being measured
The primary outcome is the main question the study is designed to answer.
Efficacy: closure of fistula at week 8 Safety: - Clinically measured abnormality of laboratory tests and adverse events
Secondary outcomes (4)
Closure of fistula
Measured: week 4
Investigator satisfaction
Measured: week 4 and week 8
Patient satisfaction
Measured: week 4 and week 8
Digital photography
Measured: day 1, week 4 and week 8
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Oct 2009 (estimated)
- Study startNov 2008
- Primary completionSep 2009
- Study completionMar 2010
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Crohn's FistulaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 9 participants (actual)
Sponsor and investigators
- Lead sponsor
- Anterogen Co., Ltd.
- Sponsor type
- Industry (pharma, biotech, devices)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00992485
- Sponsor's protocol ID
- ANTG-ASC-201
- Status last verified
- May 2010
- First submitted
- 29 Sep 2009
- Last updated
- 10 May 2010
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 May 2010. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase I Dose Escalation Clinical Study of ADIPOPLUS (Autologous Cultured Adipose-derived Stem Cell) for the Treatment of Crohn's Fistula to Evaluate Safety and Efficacy
- ClinicalTrials.gov ID
- NCT00992485
- Acronym / sponsor ID
- ANTG-ASC-201
- Conditions
- Crohn's Fistula
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 9 participants (actual)
- Lead sponsor
- Anterogen Co., Ltd.Industry (pharma, biotech, devices)
- Study start
- Nov 2008
- Primary completion
- Sep 2009 (actual)
- Study completion
- Mar 2010 (actual)
- First posted
- 9 Oct 2009 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Up to date, a sure cure for Crohn's fistula has not known and the fistula recurrence rate is high. On 15 October 2008, orphan drug designation was granted by Korea FDA to Anterogen Co. Ltd., for human adipose-derived stem cell. In this study, patients are given injection of ADIPOPLUS in fistula site and followed for 8 weeks to test the safety and efficacy.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| autologous adipose derived stem cell | Experimental | Drug: ADIPOPLUS |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Older than 18 years
- Prior diagnosis of Crohn's disease
- patients who have Crohn's fistula
- negative for urine beta-HCG for woman of childbearing age
- agreement to participate, with signed informed-consent
Key exclusion criteria (13 listed)
- patients who have allergy to bovine-derived materials or an anesthetic
- patients with a diagnosis of auto immune disease except for Crohn's disease
- Diagnosis of HBV, HCV, HIV and other infectious disease
- Patients who have a symptom of septicemia
- Patients with a diagnosis of active Tuberculosis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ADIPOPLUSautologous adipose-derived stem cell | Drug | autologous adipose derived stem cell |
Primary outcome
Efficacy: closure of fistula at week 8 Safety: - Clinically measured abnormality of laboratory tests and adverse events
4 secondary outcomes
Closure of fistula
Time frame: week 4
Investigator satisfaction
Time frame: week 4 and week 8
Patient satisfaction
Time frame: week 4 and week 8
Digital photography
Time frame: day 1, week 4 and week 8
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 May 2010.
Related trials for Crohn's Fistula
RecruitingPhase 4
Risankizumab for Refractory Perianal Fistulizing Crohn's Disease
Crohn Disease, Perianal Fistula
Recruiting
A Study Comparing Transperineal Ultrasound, Magnetic Resonance Imaging, Endoscopic Ultrasound, and Examination Under Anesthesia to Detect and Classify Perianal Fistulas in Patients With Crohn's Disease or Fistulas of Unknown Cause
Crohn Disease (CD), Cryptoglandular Perianal Fistula
Not yet recruitingPhase 4
MIRICURE: Mirikizumab With Curettage and Repair (Closure) for Perianal Fistulizing Crohn's Disease
Crohn's Disease, Perianal Fistula
RecruitingObservational study
Exclusive Enteral Nutrition Therapy for Active and Complicated Crohn's Disease
Crohn's Disease
RecruitingObservational study
Study on the Treatment of Anal Fistulas Using Alofisel Versus Fat Autologous Stem Cells
Crohn Disease, Anal Fistula
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing ADIPOPLUS in people with Crohn's Fistula, run by Anterogen Co., Ltd. at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 May 2010. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Efficacy: closure of fistula at week 8 Safety: - Clinically measured abnormality of laboratory tests and adverse events. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 May 2010.